multiple benefits, including efficient patient stratification for advanced fibrosis (F3-F4), the ability to monitor drug response and pharmacodynamics during clinical trials, and the potential to provide valuable prognostic information for clinical outcomes and mortality in patients with end-stage liver ...
Liver fibrosis/cirrhosis associated with chronic viral hepatitis impairs liver regeneration. To investigate the augmentation of FLR in associating ALPPS between patients with fibrotic/cirrhotic livers (FL) and non-fibrotic livers (NFL) and compare their short-term clinical outcomes and long-term survival...
–stages 3 and 4 cancer, including pancreatic cancer, DIPG (diffuse intrinsic pontine glioma), GBM (glioblastoma) and other brain cancers, leukemia, non-Hodgkin lymphoma, mesothelioma, liver and bile duct cancers –last stages of HIV-AIDS and cystic fibrosis –severe forms of heart disease, COPD...
Chronic liver injury leads to progressive liver fibrosis and ultimately cirrhosis, a major cause of morbidity and mortality worldwide. However, there are currently no effective anti-fibrotic therapies available, especially for late-stage patients, which
In October 2023, Akero reported that after 36 weeks of treatment, 22% of patients treated with the 28-mg dose of efruxifermin saw at least a one-stage improvement in liver fibrosis with no MASH worsening, whereas 24% of those given the higher 50-mg dose met this endpoint. The MASH...
and 0.4% died. The 3-year risk for HCC in patients with new-onset metabolic syndrome, compared with those without metabolic syndrome at both time points, was 1.3% vs 2.3%, respectively. Liver fibrosis progression but not new-onset metabolic syndrome was an independent risk factor for HCC in...
Pulmonary fibrosis occurred in less than 1% (2/1467) of patients enrolled in clinical studies of Vectibix®. In the event of acute onset or worsening of pulmonary symptoms interrupt Vectibix® therapy. Discontinue Vectibix® therapy if ILD is confirmed. In patients with...
“NASH with liver fibrosis puts patients at risk of progressing to liver failure, liver cancer, need for liver transplant and premature mortality,” study investigator Stephen Harrison, MD, of Pinnacle Clinical Research and Summit Clinical Research in San Antonio, said in the press release. “With...
2. Fig. 2. Pathological mechanisms of CKD-to-ESRD progression. Full size image One of the most important factors in the development of renal pathology is inflammation [15, 17, 18]. ESRD can also accompany glomerulosclerosis, tubulointerstitial fibrosis, and atrophy [15, 19]. Finally, ESRD is...
Indeed, monocyte-derived Macro_SPP1 represents a shared cell state in lung cancer, pulmonary fibrosis, and COVID-1989, and is predominant in liver metastasis with a pro-metastasis role90. Consistently, highly angiogenic, inflammatory, and immune-suppressed TME profiled in our study were the ...